Allergy Bioequivalence No “Day In The Park”; FDA Seeks Only One Study
Executive Summary
FDA is recommending one traditional study design for demonstrating bioequivalence in NDAs and ANDAs for nasal aerosols and sprays seeking a seasonal allergic rhinitis indication